Key result
Ischemic preconditioning reduces infarct volume ~79% via adenosine without requiring alpha-adrenergic activation.
Why the study?
The study aimed to determine whether adrenergic activation is cardioprotective, whether this protection involves adenosine receptor activation, and whether ischemic preconditioning requires alpha-adrenergic activation.
Does adrenergic activation or ischemic preconditioning reduce infarct volume via adenosine or alpha-adrenergic receptors in a rabbit model of ischemia-reperfusion?
Population
Anesthetised open chest rabbits undergoing 30 min coronary occlusion and 3 h reperfusion
Comparison
Ischemic preconditioning or adrenergic activation with tyramine, with or without adenosine or alpha-adrenergic receptor blockade
Design
Preclinical experimental study
Follow-up
3 h reperfusion
Authors
Loading...
Ischemic preconditioning's adenosine-dependent protection in rabbits extends mechanistic insights; clinical translation remains untested.
Does adrenergic activation or ischemic preconditioning reduce infarct volume via adenosine or alpha-adrenergic receptors in a rabbit model of ischemia-reperfusion?
Effect estimate: 79% reduction
p-value: p=< 0.0005
Cardioprotection from ischemic preconditioning and alpha-adrenergic activation both involve adenosine, but ischemic preconditioning does not require alpha-adrenergic activation.
Haessler et al. (1996) studied Myocardial infarction. Ischemic preconditioning and adrenergic activation (tyramine) vs. Control (no preconditioning/activation) was evaluated on Risk-adjusted infarct volume (79% reduction, p=< 0.0005). Ischemic preconditioning reduced risk-adjusted infarct volume by 79% (P<0.0005), a cardioprotective effect that involves adenosine but does not require alpha-adrenergic activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: